Who will serve on new Merck's front lines?

The big Merck headlines overlooked some of the most important news: The folks taking nitty-gritty jobs at the post-merger company. Here's a primer. Report

Suggested Articles

Zejula
Pharma

GSK cancer unit, in 'building mode,' gets picky with M&A

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

by Carly Helfand
Novo Nordisk
Pharma

Novo's Ozempic scores major win with heart-helping FDA approval

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

by Kyle Blankenship
Bayer
Pharma

Bayer's 'tumor-agnostic' Vitrakvi rejected in England, Germany

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

by Eric Sagonowsky